Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note released on Tuesday, January 9th.
According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
A number of other research firms have also weighed in on OSUR. Jefferies Group restated a buy rating and issued a $20.00 target price on shares of OraSure Technologies in a report on Tuesday, September 12th. Canaccord Genuity restated a buy rating and issued a $22.00 target price on shares of OraSure Technologies in a report on Tuesday, September 19th. BidaskClub upgraded shares of OraSure Technologies from a hold rating to a buy rating in a report on Thursday, December 21st. Finally, ValuEngine lowered shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $19.65.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.09. The company had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.11 EPS. equities analysts predict that OraSure Technologies will post 0.43 earnings per share for the current fiscal year.
In related news, Director Mara G. Aspinall purchased 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The stock was bought at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in OSUR. Pinebridge Investments L.P. bought a new position in OraSure Technologies in the 2nd quarter worth approximately $131,000. Victory Capital Management Inc. boosted its holdings in OraSure Technologies by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 1,360 shares during the period. Oppenheimer Asset Management Inc. bought a new position in OraSure Technologies in the 3rd quarter valued at $186,000. Profund Advisors LLC boosted its holdings in OraSure Technologies by 2.8% in the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 293 shares during the period. Finally, ETRADE Capital Management LLC bought a new position in OraSure Technologies in the 2nd quarter valued at $193,000. 92.80% of the stock is owned by institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.